ADC CDMOs — Bioconjugation, HPAPI & GMP Rankings · 2026

· updated as new inspection, certificate, and trial data enters the platform

ADC (Antibody-Drug Conjugate) manufacturers on CDMO Signal: 31 listed, 9 with a Signal Score. Together they have 99 FDA inspections on file (including 34 NAI, 63 VAI and 2 OAI), 3 FDA warning letters and 171 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. The score does not measure HPAPI containment, linker-payload chemistry, or whether antibody, payload and conjugation sit on one site. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.

ADC CDMOs with the most regulatory evidence on file

Catalent
76.1
Tampa, FL
24 FDA inspections · 39 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-22 · VAI
Warning letter 2025-11-20
See the evidence →
Olon
Rodano (Milano), Italy
11 FDA inspections · 44 EMA/MHRA GMP certs
Last FDA inspection: 2026-01-16 · VAI
See the evidence →
AGC Biologics
79.9
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
4 FDA inspections · 27 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-29 · NAI
See the evidence →
Piramal Pharma Solutions
86.9
Lexington, KY · Riverview, MI · Ahmedabad, IN
7 FDA inspections · 15 EMA/MHRA GMP certs
Last FDA inspection: 2026-02-13 · VAI
See the evidence →
Charles River Laboratories
86.3
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
9 FDA inspections · 11 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-01 · NAI
See the evidence →
31
CDMOs tracked
9
Fully scored
17
With FDA records
99
FDA inspections
171
EMA/MHRA GMP certs
3
Warning letters

Antibody-drug conjugates pair a targeting antibody with a cytotoxic payload via a chemical linker — a three-component process that crosses biologics, small-molecule, and HPAPI (high-potency API) disciplines. Manufacturing demands purpose-built containment (typically OEB-5), wet-chemistry linker-payload synthesis, and validated bioconjugation under GMP.

Selecting an ADC CDMO turns on commercial bioconjugation track record, containment level, the linker / payload chemistries already in their book of business (vc, mc, glucuronide; MMAE, MMAF, DM1, DM4, Dxd, calicheamicin, PBDs, etc.), drug-substance + drug-product capability, and clean FDA + EMA/MHRA inspections. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 34 NAI (no action), 63 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: Italy (76), United States (46), UNITED KINGDOM (27), Denmark (23), Germany (15).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PR
Lexington, KY · Riverview, MI · Ahmedabad, IN
86.9 96.0 7 insp · 15 GMP 2026-02-13 · VAI — —
2
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
3
WB2
Shanghai, CN · Wuxi, CN
82.7 99.6 1 insp · 4 GMP 2026-07-03 · VAI — —
4
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
5
BP
Latina, Italy
79.5 100.0 1 insp · 15 GMP 2021-11-12 · VAI — —
6
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
79.5 100.0 — None on file Available —
7
Tampa, FL
Hiring · 311 open roles
76.1 77.3 24 insp · 39 GMP 2026-05-22 · VAI
Warning letter 2025-11-20
— —
8
Basel, Switzerland
Hiring · 100+ open roles
Fully evidenced
72.8 86.6 11 insp · 8 GMP 2025-09-29 · VAI — 1 program
9
SB
Incheon, South Korea, Rockville, Maryland, USA
Hiring · 12 open roles
61.5 — — None on file Available —
—
Rodano (Milano), Italy
Also makes its own products
Profiled — 11 insp · 44 GMP 2026-01-16 · VAI — —
—
Cramlington, United Kingdom
Profiled — 3 insp · 3 GMP 2025-07-11 · VAI — —
—
United States
Also makes its own products
Profiled — — None on file — —
—
Oklahoma City, Oklahoma, USA
Profiled — — None on file — —
—
Lin-gang, Shanghai, China
Profiled — — None on file — —
—
Huntsville, Alabama, United States
Profiled — — None on file — —
—
Bubendorf, Switzerland
Also makes its own products
Profiled — 8 insp · 5 GMP 2025-11-14 · VAI — —
—
Plantation, Florida, USA
Profiled — — None on file — —
—
Biasca, Ticino, Switzerland
Profiled — 1 insp · 0 GMP 2025-02-20 · NAI — —
— Profiled — 6 insp · 0 GMP 2025-09-11 · NAI
Warning letter 2026-01-30
— —
—
North Chicago, Illinois, United States
Also makes its own products
Profiled — 7 insp · 0 GMP 2025-12-16 · VAI — —
—
Mumbai, India
Also makes its own products
Profiled — 2 insp · 0 GMP 2024-04-12 · NAI — —
—
Chongqing, China
Profiled — 1 insp · 0 GMP 2024-03-29 · NAI — —
—
Shanghai, China
Also makes its own products
Profiled — 1 insp · 0 GMP 2026-08-21 · NAI — —
—
Suzhou, Jiangsu, China
Profiled — — None on file — —
—
Taoyuan, Taiwan
Also makes its own products
Profiled — 2 insp · 0 GMP 2024-07-25 · VAI — —
—
Hyderabad, Telangana, India
Profiled — — None on file — —
—
Chongqing, China
Also makes its own products
Profiled — — None on file — —
—
Seoul, South Korea
Also makes its own products
Profiled — — None on file — —
—
Changsha, Hunan, China
Also makes its own products
Profiled — — None on file — —
—
Waukegan, Illinois, USA
Also makes its own products
Profiled — — None on file — —
—
York, Pennsylvania, USA
Profiled — — None on file — —
How we score CDMOs →

What to evaluate in a ADC (Antibody-Drug Conjugate) CDMO

HPAPI containment
Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.
Linker-payload chemistry on file
Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.
Commercial bioconjugation track record
Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.
Integrated DS + DP
Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Integrated ADC CDMOs vs multi-site coordination

ADC manufacturing has four distinct steps: monoclonal antibody production, payload synthesis, linker chemistry, and bioconjugation. Full-service ADC CDMOs — a small set including Lonza, WuXi Biologics, and Piramal Pharma Solutions — handle all four in-house. Most CDMOs specialize in one or two steps and coordinate with sponsors for the rest. Fully integrated is faster and simplifies comparability, but often comes with less flexibility on payload chemistry. Sponsors should map which steps each CDMO handles internally vs externally and price the coordination overhead accordingly — a two-CDMO ADC program typically adds 3–6 months of transfer and comparability work.

HPAPI containment for ADC payloads — what to ask

ADC payloads (tubulin inhibitors like MMAE and DM1, topoisomerase inhibitors like Dxd, DNA-damaging agents like PBDs and calicheamicin) are Category 3–5 high-potency compounds requiring specialized containment. CDMOs vary widely on containment maturity: dedicated HPAPI suites, negative-pressure isolators, single-use containment technology, and validated occupational exposure limits (OEL) below 1 µg/m³ (OEB-5). The FDA inspection record shown in the ranked table above reflects containment discipline under regulator scrutiny. Sponsors should also verify the CDMO's HPAPI-specific incident history and whether payload production is co-located with conjugation or shipped between sites.

Conjugation platform — random vs site-specific

Random cysteine or lysine conjugation is the mature ADC platform used by Kadcyla, Adcetris, Enhertu, Trodelvy and other approved ADCs; most CDMOs support it. Site-specific conjugation (engineered cysteines like ThioMab, unnatural amino acids, glycan-based like GlyCLICK) is the emerging platform for cleaner drug-antibody ratio (DAR) control and homogeneity. CDMOs differ in which conjugation platforms they've validated at GMP scale. Sponsors should confirm not just the CDMO's conjugation menu but demonstrated DAR consistency at intended commercial scale and the CDMO's process for handling homogeneity outliers.

How CDMO Signal computes the ADC ranking

The ADC Signal Score is the platform's standard four-pillar composite. Quality Compliance (35%) leans on FDA inspection classifications, Warning Letter history, and EMA/MHRA GMP certificate density — this pillar carries particular weight for ADC because HPAPI containment is inspection-verified and regulatory posture on ADC is still evolving. Operations (25%) reflects ClinicalTrials.gov sponsor and program footprint. Financial Stability (20%) draws on public/private status and parent-company backing — ADC is capital-intensive with specialized facilities, so parent-company health matters for long-cycle commercial engagements. Capacity Intelligence (20%) counts the manufacturing sites and modalities listed on the profile; job postings are not a score input. Press announcements and SEC filings are shown on profiles as company signals and do not change any score. Full weightings at cdmosignal.com/methodology.

ADC (Antibody-Drug Conjugate) CDMOs — Frequently Asked Questions

How many ADC (Antibody-Drug Conjugate) CDMOs have FDA inspection records?
CDMO Signal tracks 17 ADC (Antibody-Drug Conjugate) CDMOs with FDA inspection records and 171 EMA/MHRA GMP certificates across the group.
What's the difference between an ADC CDMO and a biologics CDMO?
A biologics CDMO makes the naked antibody (drug substance). An ADC CDMO additionally handles the cytotoxic payload synthesis and the bioconjugation step under HPAPI containment. Some large CDMOs (Lonza, Catalent) do both; others specialize in conjugation only and source the antibody from a biologics partner.
Which CDMOs have made commercially-approved ADCs?
Several CDMOs have commercial ADC track records. The rankings above show our scored ADC players — Lonza (Polivy, Padcev), Catalent (multi-program commercial conjugation), Piramal, AGC Biologics, Samsung Biologics, WuXi Biologics, Charles River — with FDA inspection and GMP detail per profile.
What HPAPI containment level should an ADC CDMO have?
OEB-5 (sub-microgram per cubic meter occupational exposure band) is the standard floor for handling MMAE, MMAF, DM1, DM4, Dxd, PBDs, and calicheamicin-class payloads. Some legacy payloads can run in OEB-4 but commercial work is OEB-5.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this ADC shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
Biologics / mAb CDMOs Oligonucleotide / ASO CDMOs Recombinant Proteins CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins Gene Therapy Cell & Gene Therapy Viral Vector